StreetInsider.com News Articles

Form 8-K Alamar Biosciences, Inc. For: Jul 15

Wed, 15 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260715/26774062.html

Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026

Tue, 14 Jul 2026 16:05:00 -0400

FREMONT, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will report financial results for the second quarter 2026 after market close on Monday, August 10, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.alamarbio.com. The webcast will be archived and available for replay after the event.

Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026

Tue, 14 Jul 2026 16:05:00 -0400

Live audio of the webcast will be available on the “Investors” section of the company website at: www.alamarbio.com. The webcast will be archived and available for replay after the event.

Alamar Biosciences launches national Alzheimer's proteomics study

Mon, 13 Jul 2026 05:43:34 -0400

Alamar Biosciences (Nasdaq: ALMR) announced a partnership with researchers at Washington University in St. Louis, the University of Wisconsin, and Indiana University to conduct a national-scale proteomics study focused on Alzheimer's disease and related dementias.

The project will profile approximately 21,000 plasma samples collected from 10,000 Alzheimer's Disease Research Center participants across the United States using Alamar's NULISAseq Neuro 220 panel, which includes a newly added eMTBR-Tau assay for blood-based measurement of tau tangle burden alongside neurodegeneration and neuroinflammation biomarkers.

The initiative is co-led by Sarah Biber, PhD, at Washington University in St. Louis; Sterling Johnson, PhD, at the University of Wisconsin;

Alamar Biosciences launches national Alzheimer's proteomics study

Mon, 13 Jul 2026 05:43:34 -0400

The initiative is co-led by Sarah Biber, PhD, at Washington University in St. Louis; Sterling Johnson, PhD, at the University of Wisconsin;

Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases

Mon, 13 Jul 2026 02:30:00 -0400

National-scale initiative will profile ~21,000 plasma samples from 10,000 Alzheimer’s Disease and Related Dementias (ADRD) participants using Alamar Biosciences' NULISAseq™ Neuro 220 panel. | Resulting dataset will be publicly accessible, linked through National Alzheimer’s Coordinating Center IDs and open to AI-driven discovery through a national data challenge. | Project is part of the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) portfolio, leveraging academic, philanthropic, and data-sharing partnerships for large-scale biomarker discovery.

Fremont, CA, July 13, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease,

Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases

Mon, 13 Jul 2026 02:30:00 -0400

Fremont, CA, July 13, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease,

Alamar Biosciences NULISA data to appear in 140+ AAIC presentations

Fri, 10 Jul 2026 06:13:56 -0400

Alamar Biosciences, Inc. (Nasdaq: ALMR) announced that its NULISA platform will be featured in more than 140 poster and session presentations at the Alzheimer's Association International Conference (AAIC), taking place July 12–15 in London, according to a company press release.

The figure represents more than four times the number of presentations featuring NULISA data at the previous AAIC, the company said.

Alamar will host a workshop on July 14 titled "Beyond p-tau217: Expanding Alzheimer's Insights with Multiplex Protein Profiling," scheduled from 1:20 to 2:00 PM BST. The session will present data from the company's eMTBR-Tau and BD-pTau217 assays, which were measured alongside

Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling

Fri, 10 Jul 2026 06:11:00 -0400

Company to host scientific workshop featuring emerging eMTBR-Tau and BD-pTau217 research data for Alzheimer’s disease detection and staging

Fremont, CA, July 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced that its NULISA™ platform will be featured in more than 140 poster and session presentations at the Alzheimer's Association International Conference (AAIC), taking place July 12-15 in London. The volume of data reflects widespread adoption of NULISA and ARGO™ HT technology among researchers studying Alzheimer’s and related dementias.

"With

Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling

Fri, 10 Jul 2026 06:11:00 -0400

Company to host scientific workshop featuring emerging eMTBR-Tau and BD-pTau217 research data for Alzheimer’s disease detection and staging

"With

Form SCHEDULE 13D/A Alamar Biosciences, Inc. Filed by: Sands Capital Life Sciences Pulse Fund II, L.P.

Tue, 07 Jul 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260707/26742482.html

Alamar Biosciences launches eMTBR-Tau blood test for Alzheimer's

Tue, 07 Jul 2026 09:12:24 -0400

Alamar Biosciences (Nasdaq: ALMR) launched what it claims is the first commercial immunoassay for eMTBR-Tau, a plasma biomarker associated with tau tangle pathology in Alzheimer's disease, according to a company press release dated July 7, 2026.

The assay is available in the NULISAseq Neuro 220 multiplexed panel kits, compatible with the company's ARGO HT instruments, and as a single-plex assay through its Technology Access Program.

A definitive Alzheimer's diagnosis requires evidence of both amyloid plaques and tau neurofibrillary tangles. Until recently, only amyloid pathology could be assessed through blood testing, via pTau-217. Measuring tau tangle burden has historically required tau PET imaging,

Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research

Tue, 07 Jul 2026 09:12:00 -0400

eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer’s disease | Immunoassay for eMTBR-Tau is available in the NULISAseq™ Neuro 220 panel and as a single-plex assay through the Technology Access Program | Data to be featured in Alamar’s workshop at AAIC 2026

Fremont, CA, July 07, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today launched the first commercial eMTBR-Tau immunoassay, now available in the NULISAseq™

Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research

Tue, 07 Jul 2026 09:12:00 -0400

Form SCHEDULE 13G Alamar Biosciences, Inc. Filed by: SHERPA HEALTHCARE FUND II, L.P.

Thu, 02 Jul 2026 08:46:00 -0400

si-local-file:///var/storage/secattach/20260702/26724506.html

Stifel Reiterates Buy Rating on Alamar Biosciences (ALMR)

Tue, 09 Jun 2026 09:08:59 -0400

Stifel analyst Daniel Arias reiterated a Buy rating and $28.00 price target on Alamar Biosciences (NASDAQ: ALMR).

The analyst commented, "We met with ALMR mgmt last week. No real new ground was broken, but the business appears to be performing well when it comes to expanding usage of the company's Argo platform. The focus thus remains on building out the instrumentation base, while driving adoption within the "beachhead" application areas – most notably neuro, where Alzheimer’s work levels seem robust. To that point, adoption of the new CNS 220 panel seems to be tracking well - and should become the flagship

Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics

Tue, 02 Jun 2026 14:43:40 -0400

NULISA™ DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices

Workflow extends NULISA into longitudinal, decentralized, and population-scale research

FREMONT, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today launched the NULISA™ Dried Blood Spot (DBS) Extraction Kit, enabling researchers to run NULISA assays on microsamples collected at home, unlocking longitudinal and decentralized translational study designs in neurology, inflammation, and population health that cannot be supported

Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics

Tue, 02 Jun 2026 14:43:40 -0400

NULISA™ DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices

Workflow extends NULISA into longitudinal, decentralized, and population-scale research

Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics

Tue, 02 Jun 2026 08:11:00 -0400

NULISA™ DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices | Workflow extends NULISA into longitudinal, decentralized, and population-scale research

Fremont, CA, June 02, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today launched the NULISA™ Dried Blood Spot (DBS) Extraction Kit, enabling researchers to run NULISA assays on microsamples collected at home, unlocking longitudinal and decentralized translational study designs in neurology, inflammation, and population health that cannot be supported by venous blood

Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics

Tue, 02 Jun 2026 08:11:00 -0400

BofA Securities Resumes Alamar Biosciences (ALMR) at Neutral

Tue, 12 May 2026 06:22:28 -0400

BofA Securities analyst Michael Ryskin resumes coverage on Alamar Biosciences (NASDAQ: ALMR) with a Neutral rating and a price target of $27.00.

For an analyst ratings summary and ratings history on Alamar Biosciences click here. For more ratings news on Alamar Biosciences click here.

Shares of Alamar Biosciences closed at $23.88 yesterday.

Leerink Partners Starts Alamar Biosciences (ALMR) at Outperform

Tue, 12 May 2026 06:08:03 -0400

Leerink Partners analyst Punee initiates coverage on Alamar Biosciences (NASDAQ: ALMR) with a Outperform rating and a price target of $35.00.

For an analyst ratings summary and ratings history on Alamar Biosciences click here. For more ratings news on Alamar Biosciences click here.

Shares of Alamar Biosciences closed at $23.88 yesterday.

TD Cowen Starts Alamar Biosciences (ALMR) at Buy

Tue, 12 May 2026 05:29:57 -0400

TD Cowen analyst Dan Brennan initiates coverage on Alamar Biosciences (NASDAQ: ALMR) with a Buy rating and a price target of $30.00.

The analyst comments "We initiate on ALMR at Buy w/a $30 PT (26% upside). Its NULISA chemistry & easy-to-use, robust Argo platform offer a one-two combo that is generating material enthusiasm at leading Pharma and A&G proteomics customers. NULISA is ultra-sensitive & can scale from 1 protein into the 100s, enabling use across R&D & diagnostics. Sales are set to more than double ('25 to '27) & grow at a 40% CAGR to '30."

For an analyst ratings summary and

TD Cowen Starts Alamar Biosciences (ALMR) at Buy

Tue, 12 May 2026 05:29:57 -0400

TD Cowen analyst Dan Brennan initiates coverage on Alamar Biosciences (NASDAQ: ALMR) with a Buy rating and a price target of $30.00.

For an analyst ratings summary and

JPMorgan Starts Alamar Biosciences (ALMR) at Overweight

Tue, 12 May 2026 03:16:48 -0400

JPMorgan analyst Casey Woodring initiates coverage on Alamar Biosciences (NASDAQ: ALMR) with a Overweight rating and a price target of $30.00.

The analyst comments: “We are initiating coverage of Alamar Biosciences (ALMR) with an Overweight rating and a DCF-derived December 2026 PT of $30. ALMR is a proteomics platform company whose proprietary Nucleic Acid Linked Immuno-Sandwich Assay (NULISA) chemistry, run on the ARGO instrument, is creating a new gold standard in protein measurement by combining ultra-high sensitivity with flexible multiplexing and full automation. ALMR has seen robust early adoption in the RUO setting, which is poised for sustainable future growth, while